{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Tang D"],"funding":["Science and Technology Innovation Project of Guangdong Medical Products Administration","Guangdong Basic and Applied Basic Research Foundation","National Natural Science Foundation of China"],"pagination":["2387402"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11404609"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["16(1)"],"pubmed_abstract":["Cholestatic liver injury results from the accumulation of toxic bile acids in the liver, presenting a therapeutic challenge with no effective treatment available to date. Andrographolide (AP) has exhibited potential as a treatment for cholestatic liver disease. However, its limited oral bioavailability poses a significant obstacle to harnessing its potent therapeutic properties and restricts its clinical utility. This limitation is potentially attributed to the involvement of gut microbiota in AP metabolism. In our study, employing pseudo-germ-free, germ-free and strain colonization animal models, along with 16S rRNA and shotgun metagenomic sequencing analysis, we elucidate the pivotal role played by gut microbiota in the C-sulfonate metabolism of AP, a process profoundly affecting its bio"],"journal":["Gut microbes"],"pubmed_title":["Gut microbiota-mediated C-sulfonate metabolism impairs the bioavailability and anti-cholestatic efficacy of andrographolide."],"pmcid":["PMC11404609"],"funding_grant_id":["S2021ZDZ042","2024B1515020093","82274193 and 82074110"],"pubmed_authors":["Fu B","Ye L","Liu Z","Hu W","Guo X","Tang D","You G","Xie C","Zhang Q","Zhao X","Wang HY"],"additional_accession":[]},"is_claimable":false,"name":"Gut microbiota-mediated C-sulfonate metabolism impairs the bioavailability and anti-cholestatic efficacy of andrographolide.","description":"Cholestatic liver injury results from the accumulation of toxic bile acids in the liver, presenting a therapeutic challenge with no effective treatment available to date. Andrographolide (AP) has exhibited potential as a treatment for cholestatic liver disease. However, its limited oral bioavailability poses a significant obstacle to harnessing its potent therapeutic properties and restricts its clinical utility. This limitation is potentially attributed to the involvement of gut microbiota in AP metabolism. In our study, employing pseudo-germ-free, germ-free and strain colonization animal models, along with 16S rRNA and shotgun metagenomic sequencing analysis, we elucidate the pivotal role played by gut microbiota in the C-sulfonate metabolism of AP, a process profoundly affecting its bio","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jan-Dec","modification":"2025-04-21T22:18:33.611Z","creation":"2025-04-05T18:42:42.694Z"},"accession":"S-EPMC11404609","cross_references":{"pubmed":["39264803"],"doi":["10.1080/19490976.2024.2387402"]}}